

**Keywords:** radiation; breast cancer; occupational exposure; cohort study

# Breast cancer risk and protracted low-to-moderate dose occupational radiation exposure in the US Radiologic Technologists Cohort, 1983–2008

D L Preston<sup>\*1</sup>, C M Kitahara<sup>2</sup>, D M Freedman<sup>2</sup>, A J Sigurdson<sup>2</sup>, S L Simon<sup>2</sup>, M P Little<sup>2</sup>, E K Cahoon<sup>2</sup>, P Rajaraman<sup>2</sup>, J S Miller<sup>3</sup>, B H Alexander<sup>4</sup>, M M Doody<sup>2</sup> and M S Linet<sup>2</sup>

<sup>1</sup>Hirossoft International, 1335 H, Eureka, CA 95501, USA; <sup>2</sup>Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850, USA; <sup>3</sup>Information Management Services Inc., 6110 Executive Boulevard No. 310, Rockville, MD 20852, USA and <sup>4</sup>Division of Environmental Health Sciences, School of Public Health, University of Minnesota, 426 Church Street SE, Minneapolis, MN 55455, USA

**Background:** Although high-dose ionising radiation is associated with increased breast cancer risks, the association with protracted low-dose-rate exposures remains unclear. The US Radiologic Technologist study provides an opportunity to examine the association between low-to-moderate dose radiation and breast cancer incidence and mortality.

**Methods:** One thousand nine hundred and twenty-two self-reported first primary cancers were diagnosed during 1983–2005 among 66 915 female technologists, and 586 breast cancer deaths occurred during 1983–2008 among 83 538 female cohort members. Occupational breast dose estimates were based on work histories, historical data, and, after the mid-1970s, individual film badge measurements. Excess relative risks were estimated using Poisson regression with birth cohort stratification and adjustment for menopause, reproductive history, and other risk factors.

**Results:** Higher doses were associated with increased breast cancer incidence, with an excess relative risk at 100 mGy of 0.07 (95% confidence interval (CI): -0.005 to 0.19). Associations were strongest for technologists born before 1930 (excess relative risk at 100 mGy = 0.16; 95% CI: 0.03–0.39) with similar patterns for mortality among technologists born before 1930.

**Conclusions:** Occupational radiation to the breast was positively associated with breast cancer risk. The risk was more pronounced for women born before 1930 who began working before 1950 when mean annual doses (37 mGy) were considerably higher than in later years (1.3 mGy). However, because of the uncertainties and possible systematic errors in the occupational dose estimates before 1960, these findings should be treated with caution.

The risk of breast cancer has been associated with moderate and high ionising radiation doses in atomic bomb survivors and radiotherapy patients (United Nations Scientific Committee on the Effects of Atomic Radiation, 2008). However, data on breast cancer risk among women exposed to protracted low-dose radiation exposure are limited. Exposure–response trends for breast cancer

have been reported for women who underwent multiple diagnostic x-rays during childhood and adolescence to assess spinal curvature from scoliosis (Ronckers *et al*, 2008) and for tuberculosis patients with repeated fluoroscopic examinations (Howe and McLaughlin, 1996; Little and Boice, 1999). A cohort study of Russians (Eidemuller *et al*, 2008; Ostroumova *et al*, 2008; Davis *et al*, 2015) with

\*Correspondence: Dr DL Preston; E-mail preston@hirossoft.net

Received 27 May 2016; revised 29 July 2016; accepted 9 August 2016; published online 13 September 2016

© 2016 Cancer Research UK. All rights reserved 0007–0920/16

low-dose-rate environmental exposures found indications of a dose-response association. Most nuclear worker studies are comprised solely of men; however, a study in the United Kingdom that included women found no evidence of an association between radiation dose and breast cancer rates (Muirhead *et al*, 2009). Most other occupational studies, including those of medical radiation workers (Linnet *et al*, 2010) and flight crews (Zeeb *et al*, 2003), were based on work history factors rather than dose estimates.

Using self-reported work history data in the US Radiologic Technologists (USRT) study, we previously reported that technologists who worked before 1950 experienced elevated breast cancer incidence (Doody *et al*, 2006) and mortality (Mohan *et al*, 2002) compared with those who first worked after 1959. Hormonal, reproductive, lifestyle, anthropometric, and other known risk factors account for ~40% of breast cancer cases (Madigan *et al*, 1995; Sprague *et al*, 2008), and our earlier analyses of breast cancer incidence in the USRT Cohort (Mohan *et al*, 2002; Doody *et al*, 2006) and the WeCare study of second breast cancers (Langholz *et al*, 2009; Bernstein *et al*, 2013) are the only studies that examined individual radiation exposure and breast cancer risks adjusting for a broad range of known lifestyle and reproductive risk factors.

The current paper, based on data from the USRT study, describes the first comprehensive dose-response analysis for breast cancer risk among medical radiation workers using individualised annual dose estimates that were based on badge dose measurements available in more recent years covering ~30% of individual worker total doses, on average, together with information on work history and practices. For each worker, we calculated mean annual breast doses from 1000 dose realisations that reflect the uncertainty in individual annual doses from various sources (Simon *et al*, 2014). Dose estimates have been corroborated by an analysis of chromosome translocation frequencies in a subset of USRT cohort members that found a radiation dose-response similar to that reported in other radiation-exposed populations (Little *et al*, 2014). Using risk factor information obtained from three detailed questionnaires administered at roughly 10-year intervals, we investigated and adjusted for confounding by a wide range of known or suspected breast cancer risk factors.

**MATERIALS AND METHODS**

**Target population and data sources.** Details of the study population and methods are given in Boice *et al* (1992) and Doody *et al* (2006) and can be found online at <http://www.radtechstudy.nci.nih.gov> (Radiation Epidemiology Branch, 2015). Briefly, in the mid-1980s, the US National Cancer Institute, in collaboration with the University of Minnesota and the American Registry of Radiologic Technologists (ARRT), began a cohort study of 146 022 radiologic technologists, including 106 953 women, who were certified for at least 2 years between 1926 and 1982 (Sigurdson *et al*, 2003). Vital status was ascertained from ARRT recertification records and linkage with the Social Security Administration. Cause of death was ascertained from the National Death Index through 31 December 2008.

Work history, behaviour, and cancer incidence data were obtained from three surveys: the first administered between 1983 and 1989 to 98 233 female technologists (71% response); the second administered to 94 508 women between 1994 and 1998 (74% response); and the third administered between 2003 and 2005 to 78 506 women (74% response) who completed at least one previous questionnaire.

**Study population and follow-up.** The target population for both incidence and mortality follow-up included 83 358 female technologists who responded to at least one questionnaire. Incidence analyses were limited to 66 915 out of the 83 358

technologists who completed at least two questionnaires and reported no cancer other than non-melanoma skin cancer before completing their first questionnaire (2366 women were excluded). Follow-up extended from the first (baseline) questionnaire answered until the earliest of a self-reported diagnosis of a cancer other than non-melanoma skin cancer or the last questionnaire answered. Mortality analyses were based on all 83 538 women who completed at least one questionnaire with follow-up from that response date until the date of death or 31 December 2008.

**Breast cancer outcomes and medical validation.** Incident cases were self-reported first primary malignancies occurring between the first and last questionnaires answered. Medical records were sought for all cases and obtained for 1611 of 1934 (83%), of which all but 12 (99%) were confirmed. We excluded the latter. Because medical records were obtained for a high percentage of self-reported cases, nearly all of which were confirmed, the 323 self-reported breast cancers for which medical records could not be obtained were treated as cases. Thus, the study included 1922 incident cases. Mortality analyses were based on 586 breast cancer deaths, 80% of which had been reported as an incident cases on at least one questionnaire.

**Dose estimation.** Dose reconstruction was undertaken to estimate individual annual occupational absorbed doses to specific organs (Simon *et al*, 2014). Input data included: 684 465 annual badge dose measurements for 83 719 female cohort members between 1960 and 1997 from the nation's largest commercial dosimetry provider, military radiation dose registries, civilian employers, and a major US hospital; detailed information on work procedures and protection practices obtained from the cohort surveys; and literature-derived historical data on badge doses, x-ray imaging technology, radiation protection standards, protection practices, radiation energies and filtration; and other factors affecting exposure (Simon *et al*, 2014, 2006). The system provides 1000 realisations of breast dose for each cohort member in each year worked. The individual annual dose estimates used for these analyses were the arithmetic means of the 1000 realisations. Tables 1 and 2 present summary information on the doses. Further details on the dosimetry system are given in (Simon *et al*, 2014) and Supplementary Data A.

**Statistical methods.** Our *a priori* approach for the dose-response analyses was to focus on breast cancer incidence using internal comparisons of excess relative risk (ERR) stratified by birth cohort

**Table 1. Summary information on dose, years worked, and year of birth by period worked, US Radiologic Technologists study, 1983–2008**

Period worked	Total years worked	Mean years worked in period	Mean annual breast dose (mGy)	Badge dose available (%) <sup>a</sup>	Mean birth year
Pre-1930	390	3	84.6	0	1905
1930–1939	4016	4.3	82.2	0	1912
1940–1949	18 469	4.4	26.5	0	1921
1950–1959	66 033	4	7.4	0	1933
1960–1969	176 351	4.7	2.8	1	1941
1970–1979	415 873	5.8	1.5	18	1949
1980–1989	497 654	7.5	0.6	61	1949
1990+	356 814	6.7	0.3	73	1950
Total	1 535 600	6.2	1.9	42	1947

Abbreviation: mGy = milliGray.  
<sup>a</sup>Percentage of annual dose estimates for which a badge dose reading was available.

**Table 2.** Summary information on dose, years worked, and year of birth by year first worked, US Radiologic Technologists study, 1983–2008

Year first worked	Women	Mean total years worked	Mean total cumulative breast dose (mGy)	Mean birth year
Pre-1930	131	28.1	1168	1905
1930–1939	814	21.0	556	1913
1940–1949	3339	20.1	180	1923
1950–1959	12 100	18.2	50	1935
1960–1969	25 620	19.9	27	1945
1970–1979	40 379	17.4	14	1954
1980+	1155	11.4	6	1951
Total	83 538	18.4	37	1947

Abbreviation: mGy = milliGray.

and year first worked based on findings from our earlier work-history analyses. We also assessed excess absolute risks. As a secondary component of our analysis, we examined dose–response ERR for breast cancer mortality. In sensitivity analyses, we evaluated dose–response ERR for breast cancer incidence using external comparisons with US incidence rates from SEER population-based cancer registries.

Poisson regression was used to calculate ERRs and 95% confidence intervals (CIs) for breast cancer incidence or mortality, in a person-year table stratified by age, 5-year lagged cumulative breast dose, and other factors (for more details see Supplement Data B). Rates were described using ERR models of the form  $\lambda_0(a, b, z_0) [1 \text{ ERR}(d, z_1)]$ , in which  $\lambda_0(a, b, z_0)$  represents the background rates depending on age ( $a$ ), birth cohort ( $b$ ) and other factors ( $z_0$ ). The ERR depends on dose ( $d$ ) and, as necessary, various effect modifiers ( $z_1$ ). The primary risk model is described in detail in Supplementary Data D.

We evaluated known or suspected breast cancer risk factors to identify those which improved model fit or had an appreciable effect on inference about the radiation dose–response. Factors included in the final models were attained age, birth cohort, number of live births, menopausal status, body mass index (BMI) at baseline, family breast cancer history, alcohol consumption, and use of hormone replacement therapy. Other potential risk factors, including race, marital status, smoking, and other reproductive factors were not included in the primary analyses as their inclusion neither improved model fit nor had any appreciable effect on inference about the radiation dose–response association. With the exception of menopause age and status, missing data for risk factors were represented by missing-value indicator variables. A single imputation method was used to assign menopause age to women who were premenopausal at the time of last reported menopause status (Supplementary Data C). Standardised incidence/mortality ratio (SIR, SMR) analyses based on SEER incidence and mortality rates (Surveillance Epidemiology and End Results (SEER) Program, 2015) were used for some supplementary analyses.

Maximum-likelihood estimates were computed using AMFIT (Preston *et al*, 2015). Two-sided hypothesis tests and CIs were based on likelihood ratio tests (Cox and Hinkley, 1974).

## RESULTS

**Incidence.** Among 66 915 women with 1 089 502 years of follow-up and 1922 reported first primary breast cancers, incidence

increased with age with a complex interaction between age and menopausal status. Supplementary Data D contains information on the fitted rate model and includes a plot illustrating how rates varied with age, birth cohort, and menopausal age. Incidence did not vary substantially by race or marital status, but was higher in those with more education, current and former smokers, greater reported alcohol consumption, higher BMI at baseline, and a family history of breast cancer (see Supplementary Table D1 for details). Risks were higher in nulliparous women, declined with increasing number of children, and were slightly increased among those using hormone replacement therapy (see Supplementary Table D2 for details). There was no association with age at menarche. Age-specific breast cancer rates have decreased markedly with increasing birth year in the USRT (Supplementary Table D1).

The magnitude of the estimated linear ERR dose–response slope depended on the nature of the birth cohort adjustment. Without birth cohort adjustment, there was a positive dose–response association ( $P < 0.001$ ) with an estimated ERR at 100 mGy of 0.12 (95% CI: 0.03–0.25). In contrast, using a simple log-linear adjustment for birth cohort, the estimated ERR at 100 mGy was 0.05 (95% CI: -0.02 to 0.16;  $P = 0.4$ ). Adjustment for birth cohort had little effect on other parameters in the risk model (Supplementary Table D1). In view of the unusual nature of the simple birth cohort trend, our primary analyses were stratified on birth cohort. We also examined the extent to which the breast cancer risk varied with time-dependent length of employment as a radiological technologist. These analyses (details not shown) provided no indication of a significant trend in risk with employment duration and the estimated magnitude of the trend was small, ~1% change in risk per decade increase in employment length.

The upper portion of Table 3 and Figure 1A present results of a stratified analysis with separate ERR estimates for each of four birth cohorts (before 1930, 1930–1939, 1940–1949, and 1950+). Supplementary Table D2 contains information on the birth cohort-specific distributions of various risk factors. A linear dose–response association was observed for cohort members born before 1930 with an estimated ERR at 100 mGy of 0.16 (95% CI: 0.03–0.39). There was no indication of a positive dose–response association in the other birth cohorts and weak evidence of heterogeneity ( $P = 0.08$ ). When the ERR was assumed constant over strata, the estimate (ERR at 100 mGy = 0.07; 95% CI: -0.10 to 0.19,  $P = 0.09$ ) was slightly larger than that in an unstratified model in which baseline rates were assumed to vary log-linearly with birth cohort. Table 4 presents ERR estimates within year first worked categories (before 1950, 1950–1959, 1960–1969, and 1970+). There was a dose–response association in the earliest category (ERR at 100 mGy = 0.11) with no indication of increased risks for the other three groups, but only weak evidence of heterogeneity over first year worked categories ( $P = 0.10$ ). Estimated excess absolute rates exhibited similar variation by birth cohort (results not shown).

The SEER-based SIR estimate was 1.08 (95% CI: 1.04–1.14). Birth cohort-specific ERR estimates in an SIR model were similar to those from parametric models (details not shown).

**Mortality.** The mortality analyses were based on 83 538 women in the USRT Cohort with 1 722 303 years of mortality follow-up who completed at least one study questionnaire. There were 586 breast cancer deaths, of which 119 were in women who self-reported breast cancer and were included in the cohort of 66 915 women in the incidence analyses who completed at least two study questionnaires and 349 among women who reported a breast cancer diagnosis before the date of completion of the first survey. Only 20% (118) of the breast cancer deaths occurred among women who had never reported breast cancer. While breast cancer

**Table 3. ERR estimates for breast cancer incidence and mortality by birth cohort, US Radiologic Technologists study, 1983–2008**

Year of birth	ERR at 100 mGy <sup>a</sup>	95% CI	P-value	Fitted excess cases	Observed cases	Mean dose (mGy)
<b>Incidence</b>						
Before 1930	0.16	0.03, 0.39	0.01	44.2	216	167
1930–1939	–0.1	< –0.3, 0.11	0.41	–21	406	49
1940–1949	–0.14	< –0.5, 0.22	0.4	–25.8	745	25
1950+	–0.25	< –0.5, 0.31	0.27	–27.9	555	14
			$P_{\text{het}} = 0.08$			
Common ERR	0.07	–0.005, 0.19	0.09	54.3	1922	30
<b>Mortality</b>						
Before 1930	0.26	0.08, 0.63	<0.001	43.7	128	217
1930–1939	0.28	–0.08, 0.89	0.26	19.5	159	51
1940–1949	1.61	0.20, 4.50	0.01	52.6	190	25
1950+	0.61	< –0.5, 4.70	>0.5	8.6	109	14
			$P_{\text{het}} = 0.35$			
Common ERR	0.31	0.11, 0.67	<0.001	88.5	586	37

Abbreviations: BMI = body mass index; CI = confidence interval; ERR = excess relative risk;  $P_{\text{het}}$  = P-value of test for heterogeneity over birth cohorts.  
<sup>a</sup>Adjusted for attained age, birth cohort category, menopause status, family history of breast cancer, baseline BMI and use of hormone replacement therapy.

was the most common cause of death among the 1922 breast cancer cases in the incidence analyses, most of the women in this group (87%) were still alive at the end of the mortality follow-up.

The associations between non-radiation lifestyle and reproductive factors and breast cancer mortality were generally similar to those seen for incidence. Age-specific breast cancer mortality rates for cohort members decreased over time (see Supplement Data E for details).

Without birth cohort adjustment, there was a positive dose–response association ( $P < 0.001$ ) with an ERR at 100 mGy of 0.71 (95% CI: 0.31–1.43) and no evidence of non-linearity ( $P > 0.5$ ). As shown in the lower portion of Table 3, in a stratified analysis in which the ERR was assumed to be the same in all birth cohorts, the estimated ERR at 100 mGy was 0.31 ( $P < 0.001$ ). Although there was no evidence of significant heterogeneity in the ERRs over birth cohort ( $P = 0.35$ ), as with incidence, the experience of the early workers is the primary determinant of the risk (see Table 3 and Figure 1B). As with incidence, when birth cohort associations were described using a log-linear birth cohort trend, evidence for a radiation association was greatly reduced: the estimated ERR at 100 mGy was essentially zero (95% CI: < –0.03 to 0.10;  $P > 0.5$ ). An SMR analysis indicated that mortality was slightly lower than expected (SMR = 0.9; 95% CI 0.82–0.97) with birth cohort-specific ERR estimates similar to those based on internal comparisons (details not shown).

## DISCUSSION

Analyses of breast cancer incidence and mortality rates in the USRT Cohort stratified on birth cohort suggest that low-to-moderate-dose protracted occupational radiation exposure is associated with increased breast cancer risk. Statistically significant trends were seen for incidence and mortality among women born before 1930. The findings, especially for incidence, are less clear for more recent birth cohorts where lifetime cumulative doses are much lower.

There were no indications of a dose–response association for either incidence or mortality when the variation in age-specific rates with birth cohort was modelled using continuous log-linear or log-quadratic functions of birth year. However, using such simple parametric birth cohort trend models may underestimate the radiation dose–response association because of intrinsic confounding between estimated cumulative breast dose and birth

year ( $r = -0.58$ ) and the marked variation in age-specific rates with birth cohort. The effect of this confounding is exacerbated by the large uncertainties in individual dose estimates for the early (higher dose) years when badge dose readings were unavailable. Concern about intrinsic confounding is supported by the contrast between the decline in age-specific incidence rates with birth cohort in the USRT study and the increase with some leveling off in recent years seen in US cancer registry data (Devesa *et al*, 1995; Edwards *et al*, 2014) and in age period cohort analyses of Danish (Anderson *et al*, 2013) and Norwegian (Weedon-Fekjaer *et al*, 2012) population data.


Age-specific breast cancer mortality rates have declined over time in the USRT Cohort, a pattern broadly similar to that seen in age-standardised US breast cancer mortality rates (Tarone *et al*, 1997; Jatoi *et al*, 2005). However, the marked effect of adjusting for birth cohort using smooth models on the radiation dose–response further suggests confounding between dose and birth cohort.

Despite this confounding, both the incidence and mortality data indicated that radiation is associated with increased breast cancer risks in the earliest workers with little evidence of increased risk in more recent workers who received lower doses. The findings from the mortality analyses are consistent with results of the work-history-based analyses that showed increased breast cancer mortality for those who started working before 1950. As there was some indication of heterogeneity in the radiation ERRs with year first worked or birth cohort, the birth cohort-stratified analyses with a single ERR trend estimate appear to provide the most useful characterisation of the breast cancer dose–response association.

The USRT has a number of strengths. It is a large nationwide cohort with individualised dose estimates, long-term follow-up, detailed information on potential confounders, and a high confirmation rate for the self-reported incident cases. The individualised bone marrow dose estimates were used in a dose–response analysis of chromosome translocation frequency (Little *et al*, 2014) that found radiation dose–response trends similar to those seen in other populations.

This study has a number of limitations. For technologists who began working in more recent decades, power to detect associations was limited owing to low cumulative occupational radiation doses. Incidences may have been under-reported during follow-up as this information was captured in follow-up surveys administered every 8 to 10 years. Underascertainment of breast cancers should not have led to biased risk estimates unless cohort members with higher doses were more likely to report a case or if dose was more





**Figure 1.** Birth cohort-specific fitted breast cancer incidence (**A**) and mortality (**B**) dose-response curves (solid lines) with categorical excess relative risk estimates (ERRs) (closed circles) and 95% confidence limits. The dashed lines are the fitted linear dose-response curves assuming that the ERR is the same in all birth cohorts.

strongly associated with aggressive and rapidly fatal breast tumour types that were less likely to have been captured via self-report. However, Freedman *et al* (2006) found that only ~3% of breast cancers were not reported by survey respondents, suggesting that underascertainment is unlikely to be an important source of bias. As dose estimates and risk factor data were available only for technologists who survived to at least the mid-1980s or, for the incidence analyses, the mid-1990s, older and higher dose technologists are under-represented in these analyses. While this reduces the power of the study, it seems unlikely that it would bias the risk estimates for the study period.

Despite the carefully designed dosimetry system, uncertainties, and, more importantly, the potential for systematic errors in the dose estimates before 1960, and for most cohort members, the mid-1970s, for the early years when badge dose measurements were lacking and information on dose distributions is scarce are the most important limitations of this analysis. Only ~30% of individual worker total doses were based on actual badge readings. The correlation between birth cohort and total cumulative dose, together with the uncertainty in the dose estimates (particularly for the early years), make it difficult to disentangle birth cohort and dose-response associations. Lifestyle differences between early

**Table 4. ERRs and 95% CIs for breast cancer incidence by year first worked, US Radiologic Technologists study, 1983–2008**

Year first worked	ERR at 100 mGy <sup>a</sup>	95% CI	P-value	Fitted excess cases	Observed cases	Mean dose (mGy)
Before 1950	0.11	0.03, 0.39	0.03	31	163	213
1950–1959	–0.04	< –0.3, 0.11	>0.5	–8.6	450	49
1960–1969	–0.19	< –0.5, 0.22	0.18	–25.8	684	26
1970+	–0.33	< –0.5, 0.33	0.22	–27.9	625	14
Phet = 0.10						
Common ERR	0.07	–0.005, 0.19	0.07	54.3	1922	30

Abbreviations: BMI = body mass index; CI = confidence interval; ERR = excess relative risk; mGy = milliGray.

<sup>a</sup>Adjusted for attained age, birth cohort category, menopause status, family history of breast cancer, baseline BMI and use of hormone replacement therapy.

**Table 5. ERR estimates for breast cancer incidence and mortality in the USRT study (1983–2008) and previous studies**

	Incidence			Mortality		
	Cases	ERR at 100 mGy	95% CI	Deaths	ERR at 100 mGy	95% CI
USRT study	1922	0.07	–0.005, 0.19	586	0.31	0.11, 0.67
Atomic bomb survivors <sup>a</sup>	1073	0.19 <sup>b</sup>	0.12, 0.28	324	0.16	0.09, 0.24
Pooled analysis <sup>c</sup>	245	0.07	0.04, 0.12			
Techa River Cohort <sup>d</sup>	109	0.19	–0.06, 0.61			
Mayak Worker Cohort <sup>e</sup>				107	0.02	–0.01, 0.06

Abbreviations: CI = confidence interval; ERR = excess relative risk; mGy = milliGray; USRT = US Radiologic Technologists.

<sup>a</sup>From Preston *et al* (2007) (incidence) and Ozasa *et al* (2012) (mortality).

<sup>b</sup>Scaled to attained age 50 years to correspond to the average attained age at diagnosis in the current USRT data.

<sup>c</sup>The estimate shown here was based on the results for the three US cohorts used in that analysis (the two Massachusetts tuberculosis cohorts and a US thymic irradiation cohort) for the pooled ERR model shown in Table 9 of Preston *et al* (2002). The estimate corresponds to the ERR at attained age 50 years.

<sup>d</sup>From Davis *et al* (2015).

<sup>e</sup>From Sokolnikov *et al* (2015).

workers and the general population may account for some of the unusual birth cohort trends, but the persistence of these differences after adjustment and the similarity of the risk factor associations to those observed in other studies (Colditz *et al*, 2006), suggests that lifestyle differences are unlikely to account for the patterns observed. Table 5 contrasts the breast cancer incidence and mortality ERR estimates for the USRT population with those from several other cohort studies. Although the USRT mortality risk estimate is roughly two times that in atomic bomb survivor studies (Preston *et al*, 2007; Ozasa *et al*, 2012), the incidence ERR for the current analysis is similar to the risks for cohorts in the pooled analysis of atomic bomb survivors and patients exposed to radiation from medical sources (Preston *et al*, 2002). The difference in the ERRs for Japanese and western women appeared to be largely due to marked differences in the baseline rates in Japan from those in western countries. The latest incidence ERR estimate in the cohort of Russian women who received chronic low-dose-rate environmental exposures (Davis *et al*, 2015) is only slightly higher than that seen in this study, whereas the breast cancer mortality ERR in the Mayak plutonium production workers (Sokolnikov *et al*, 2015) was somewhat lower than our USRT estimate.

The USRT is the first large cohort of medical radiation workers with dose estimates based on a comprehensive, individualised dose reconstruction, extended follow-up, large numbers of female technologists and breast cancer cases, and extensive information on breast cancer risk factors and potential confounders. Despite the difficulty of disentangling variations in breast cancer rates with dose and birth cohort and the shortcomings of the early-worker dose estimates, a radiation dose–response association was observed for both incidence and mortality in those born before 1930.

Occupational radiation dose to the breast was positively associated with breast cancer risk. The risk was more pronounced for women born before 1930 who began working before 1950 when mean annual doses (37 mGy) were considerably higher than in later years (1.3 mGy). However, because of the uncertainties and possible systematic errors in the occupational dose estimates before 1960 these findings should be treated with caution.

#### ACKNOWLEDGEMENTS

JS Miller, DL Preston, and MM Doody had primary responsibility for data preparation. DL Preston organised the data, carried out the primary analyses, and drafted the paper. SL Simon, JS Miller, and DL Preston worked on the development of the dosimetry system. All authors participated in preparing the final version of the paper. The authors are grateful for the detailed and helpful comments of the three referees.

We thank the radiologic technologists who participated in the study, Jerry Reid of the American Registry of Radiologic Technologists for continued support, and Diane Kampa and Allison Iwan of the University of Minnesota for data management and collection. We are also grateful to Drs. Amy Berrington de Gonzalez and Robert Hoover for helpful suggestions. This research was funded by the intramural program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

This work was supported by the Intramural Research Program of the National Institutes of Health and the National Cancer Institute

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## REFERENCES

- Anderson WF, Rosenberg PS, Petito L, Katki HA, Ejlersten B, Ewertz M, Rasmussen BB, Jensen MB, Kroman N (2013) Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. *Int J Cancer* **133**(9): 2201–2206.
- Bernstein JL, Thomas DC, Shore RE, Robson M, Boice Jr JD, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Telled L, Teraoka SN, Begg CB, Olsen JH, Møller M, Liang X, Diep AT, Borg A, Concannon P, Haile RW. Group WSC (2013) Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. *Eur J Cancer* **49**(14): 2979–2985.
- Boice Jr JD, Mandel JS, Doody MM, Yoder RC, McGowan R (1992) A health survey of radiologic technologists. *Cancer* **69**(2): 586–598.
- Colditz GA, Baer HJ, Tamimi RM (2006) Breast cancer. In *Cancer Epidemiology and Prevention*, Schottenfeld Jr D, Fraumeni FJ (eds) 2nd edn, Chapter 51, pp 995–1012. Oxford University Press: Oxford, UK.
- Cox DR, Hinkley DV (1974) *Theoretical Statistics*. Chapman & Hall: New York, NY, USA.
- Davis F, Krestinina LY, Preston D, Epifanova S, Degteva M, Akleyev A (2015) Solid cancer incidence in the Techa River Incidence Cohort: 1956–2007. *Radiat Res* **184**(1): 56–65.
- Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF Jr (1995) Recent cancer trends in the United States. *J Natl Cancer Inst* **87**(3): 175–182.
- Doody MM, Freedman DM, Alexander BH, Hauptmann M, Miller JS, Rao RS, Mabuchi K, Ron E, Sigurdson AJ, Linet MS (2006) Breast cancer incidence in U.S. radiologic technologists. *Cancer* **106**(12): 2707–2715.
- Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Ehemann CR, Ward EM (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. *Cancer* **120**(9): 1290–1314.
- Eidemüller M, Ostroumova E, Krestinina L, Akleyev A, Jacob P (2008) Analysis of solid cancer mortality in the Techa River cohort using the two-step clonal expansion model. *Radiat Res* **169**(2): 138–148.
- Freedman DM, Sigurdson AJ, Doody MM, Love-Schnur S, Linet MS (2006) Comparison between cancers identified by state cancer registry, self-report, and death certificate in a prospective cohort study of US Radiologic Technologists. *Int J Epidemiol* **35**(2): 495–497.
- Howe GR, McLaughlin J (1996) Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. *Radiat Res* **145**(6): 694–707.
- Jatoi I, Anderson WF, Rao SR, Devesa SS (2005) Breast cancer trends among black and white women in the United States. *J Clin Oncol* **23**(31): 7836–7841.
- Langholz B, Thomas DC, Stovall M, Smith SA, Boice Jr JD, Shore RE, Bernstein L, Lynch CF, Zhang X, Bernstein JL (2009) Statistical methods for analysis of radiation effects with tumour and dose location-specific information with application to the WECARE study of asynchronous contralateral breast cancer. *Biometrics* **65**(2): 599–608.
- Linet MS, Kim KP, Miller DL, Kleinerman RA, Simon SL, Berrington de Gonzalez A (2010) Historical review of occupational exposures and cancer risks in medical radiation workers. *Radiat Res* **174**(6): 793–808.
- Little MP, Boice JD Jr (1999) Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. *Radiat Res* **151**(2): 218–224.
- Little MP, Kwon D, Doi K, Simon SL, Preston DL, Doody MM, Lee T, Miller JS, Kampa DM, Bhatti P, Tucker JD, Linet MS, Sigurdson AJ (2014) Association of chromosome translocation rate with low dose occupational radiation exposures in U.S. Radiologic Technologists. *Radiat Res* **182**(1): 1–17.
- Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. *J Natl Cancer Inst* **87**(22): 1681–1685.
- Mohan AK, Hauptmann M, Linet MS, Ron E, Lubin JH, Freedman DM, Alexander BH, Boice Jr JD, Doody MM, Matanoski GM (2002) Breast cancer mortality among female radiologic technologists in the United States. *J Natl Cancer Inst* **94**(12): 943–948.
- Muirhead C, O'Hagan J, Haylock R, Phillipson M, Willcock T, Berridge G, Zhang W (2009) Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers. *Br J Cancer* **100**(1): 206–212.
- Ostroumova E, Preston D, Ron E, Krestinina L, Davis F, Kossenko M, Akleyev A (2008) Breast cancer incidence following low-dose rate environmental exposure: Techa River Cohort, 1956–2004. *Br J Cancer* **99**(11): 1940–1945.
- Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, Sakata R, Sugiyama H, Kodama K (2012) Studies of the mortality of atomic bomb survivors, Report 14, 1950–2003: an overview of cancer and noncancer diseases. *Radiat Res* **177**(3): 229–243.
- Preston DL, Lubin JH, Pierce DA, McConney ME, Shilnikova NS (2015) *Epicure Risk Regression and Person-Year Computation Software: Command Summary and User Guide*. Risk Sciences International: Ottawa, ON, Canada.
- Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice Jr JD (2002) Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. *Radiat Res* **158**(2): 220–235.
- Preston DL, Ron E, Tokoku S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K (2007) Solid cancer incidence in atomic bomb survivors: 1958–1998. *Radiat Res* **168**(1): 1–64.
- Radiation Epidemiology Branch (2015) *United States Radiologic Technologists (USRT) Study: Homepage*. National Cancer Institute: Bethesda, MD USA.
- Ronckers CM, Doody MM, Lonstein JE, Stovall M, Land CE (2008) Multiple diagnostic X-rays for spine deformities and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* **17**(3): 605–613.
- Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, Hauptmann M, Mohan AK, Yoshinaga S, Hill DA, Tarone R, Mabuchi K, Ron E, Linet MS (2003) Cancer incidence in the US radiologic technologists health study, 1983–1998. *Cancer* **97**(12): 3080–3089.
- Simon SL, Preston DL, Linet MS, Miller JS, Sigurdson AJ, Alexander BH, Kwon D, Yoder RC, Bhatti P, Little MP, Rajaraman P, Melo D, Drozdovitch V, Weinstock RM, Doody MM (2014) Radiation organ doses received in a nationwide cohort of U.S. Radiologic technologists: methods and findings. *Radiat Res* **182**(5): 507–528.
- Simon SL, Weinstock RM, Doody MM, Neton J, Wenzl T, Stewart P, Mohan AK, Yoder RC, Hauptmann M, Freedman DM, Cardarelli J, Feng HA, Bouville A, Linet M (2006) Estimating historical radiation doses to a cohort of U.S. radiologic technologists. *Radiat Res* **166**(1, Part 2): 174–192.
- Sokolnikov M, Preston D, Gilbert E, Schonfeld S, Koshurnikova N (2015) Radiation effects on mortality from solid cancers other than lung, liver, and bone cancer in the Mayak Worker Cohort: 1948–2008. *PLoS One* **10**(2): e0117784.
- Sprague BL, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2008) Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. *Am J Epidemiol* **168**(4): 404–411.
- Surveillance Epidemiology and End Results (SEER) Program (2015) SEER\*Stat Database: Mortality – All COD, Aggregated With State, Total U.S. (1969–2012) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015. Underlying mortality data provided by NCHS. Available at: [www.cdc.gov/nchs](http://www.cdc.gov/nchs).
- Tarone RE, Chu KC, Gaudette LA (1997) Birth cohort and calendar period trends in breast cancer mortality in the United States and Canada. *J Natl Cancer Inst* **89**(3): 251–256.
- United Nations Scientific Committee on the Effects of Atomic Radiation (2008) *Effects of Ionizing Radiation – UNSCEAR 2006 Report to the General Assembly with Scientific Annexes A and B*. 6th edn, Vol. I, United Nations Sales No. E.08.IX. United Nations: New York, NY, USA.

Weedon-Fekjaer H, Bakken K, Vatten LJ, Tretli S (2012) Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. *BMJ* **344**: e299.

Zeeb H, Blettner M, Langner I, Hammer GP, Ballard TJ, Santaquilani M, Gundestrup M, Storm H, Haldorsen T, Tveten U, Hammar N, Linnertsjo A, Velonakis E, Tzonou A, Auvinen A, Pukkala E, Rafnsson V, Hrafnkelsson J (2003) Mortality from cancer and other causes among

airline cabin attendants in Europe: a collaborative cohort study in eight countries. *Am J Epidemiol* **158**(1): 35–46.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)